Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 8, 2025 • 2:00 PM ET

Date/Time Source News Release
06/05/2025 09:00 AM EDT PR Newswire Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
05/30/2025 07:00 AM EDT PR Newswire Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
05/07/2025 04:01 PM EDT PR Newswire Scinai Announces Annual Financial Results for 2024
05/01/2025 07:00 AM EDT PR Newswire Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases
03/27/2025 09:25 AM EDT PR Newswire Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
03/17/2025 07:00 AM EDT PR Newswire Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025
03/05/2025 07:30 AM EST PR Newswire SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT
01/06/2025 07:31 AM EST PR Newswire Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences
12/16/2024 09:25 AM EST PR Newswire Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
12/05/2024 08:25 AM EST PR Newswire Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
Page

Additional News

As of June 8, 2025 • 2:00 PM ET

Date/Time Source News Release
06/05/2025 10:05 AM EDT BioMedWire BioMedNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Italian Clearance for Option to Acquire Biotech Firm Pincell
05/30/2025 09:55 AM EDT SeekingAlpha Scinai Immunotherapeutics reports Q1 results
05/30/2025 09:25 AM EDT BioMedWire BioMedNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q1 Revenue Growth Driven by CDMO Contracts, Net Loss Narrows
05/08/2025 09:14 AM EDT BioMedWire BioMedNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports $4.8 Million Net Gain in 2024, Driven by Loan-to-Equity Conversion
05/07/2025 05:46 PM EDT SeekingAlpha Scinai Immunotherapeutics reports FY results
05/01/2025 10:09 AM EDT InvestorBrandNetwork BioMedNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Host Webinar on PC111 Antibody for Rare Skin Disorders 
03/27/2025 10:05 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell
03/17/2025 09:10 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Present at BIO-Europe Spring 2025
03/05/2025 09:39 AM EST InvestorBrandNetwork BioMedNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters $10 Million Standby Equity Purchase Agreement
03/05/2025 07:49 AM EST SeekingAlpha Scinai Immunotherapeutics announces $10M standby equity purchase agreement
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.